Oral GLP-1 Obesity Market: Assessing Roche CT-996 Ph1 Data
🚨 Last week (7/17), Genentech (member of $RHHBY) reported Ph1 data for its oral GLP-1 obesity drug, CT-996.
CT-996 - $RHHBY acquired from Carmot Therapeutics
"designed to be a biased GLP-1 receptor agonist that activates cAMP signaling with minimal-to-no beta-arrestin recruitment. These finely-tuned signaling properties are expected to lead to strong glycemic control, significant weight loss and good tolerability." (Genentech PR)
$RHHBY statement re: potential for CT-996 applies to oral obesity candidates in general:
"CT-996 is anticipated to be used not only as a therapy for achieving glycemic control and inducing weight loss, but also potentially for oral weight maintenance therapy following weight loss induced by injectables"
➡️ The bolded indication seems especially valuable given the difficulty people have staying on injectables.
$VKTX and $GPCR have fallen by -10% and -20%, respectively, since Jul 16th. 📉
Did the market over-react? 🤔
See table in tweet from @ohadhammer 👇 for detailed comparison of oral GLP-1's (mono and dual)
For oral obesity drugs...
Small molecule 🆚 peptide is a big advantage because of mfg/supply issues for peptides 🏭
🤮Nausea/vomiting is a big issue too
➡️ No detailed public data for many of the candidates re: nausea/vomiting
➡️ 73%/47% killed twice daily $PFE Danuglipron (but once daily is advancing)
➡️ Of those that have reported vomiting data, only VK2735 had no vomiting
➡️ For CT-996 encouraging that there were no discontinuations related to the study drug
But what did $RHHBY mean by the following statement? 🤔💭
"CT-996 was well tolerated, with mostly mild or moderate gastrointestinal-related adverse events, consistent with the safety profile of the incretin drug class."
% Nausea? % Vomiting?
Overall, oral GLP-1s have great market potential, but seems that the jury is still out on which of the candidates will be the winners. ⚖️
Several smid-cap obesity readouts still to come in 2024 (See 📸)
🔔 Want to unlock MORE info on these obesity smid-caps?
» Q1 '24 Hedge fund holdings
» % Holdings of our BPIQ Portfolios
» Cash, EV, short interest etc.
👉 Subscribe to BPIQ Premium Today!
This article is not investment or legal advice.
Article history:
First published: 7/25/24 EJV, AV, DG
#VKTX #GPCR #RYTM #VERU #PTN #TERN #ZLDPF
#NVO #AMGN #PFE #RHHBY